Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT03860272
Phase: Phase 1
Trial Summary: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineere – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): Agenus Inc.
Acronym:

Pin It on Pinterest